info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +1-315-636-4233    uk UK: +44-162-237-0614     in IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
 
Home » Healthcare » Hormone Replacement Therapy Market Size & Trends, 2030

Hormone Replacement Therapy Market By Therapy Type (Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, Progestogen Hormone Replacement Therapy), Route Of Administration (Oral, Parenteral, Others) By Geography, Size, Forecast, 2021-2030

Published On: Jan-2022   |   Base Year: 2021   |   No Of Pages: 140   |   Historical Data: 2015 - 2019   |   Formats: PDF   |   Report ID: 67307763

Industry Report and Statistics (Facts & Figures) - Number of Therapies & ASP by Therapy Type & Route of Administration

The global hormone replacement therapy market will witness a robust CAGR of 7.83%, valued at $24.97 billion in 2021, expected to appreciate and reach $49.25 billion by 2030, confirms Strategic Market Research.  

Hormone Replacement Therapy Market Infographics

Hormone replacement therapy (HRT) is a treatment procedure for replacing and replenishing hormones in the human body that are at inadequate levels compared to those required for normal physiology. The most well-known application of HRT is in the treatment of menopause symptoms. In other words, Hormone replacement therapy is a medical procedure in which patients are given hormones to replace naturally occurring hormones or augment naturally occurring ones that are missing. In the case of females, this treatment is used to restore the hormone levels in women who are at the stage of menopause, allowing the body to operate normally.

 

Hormone replacement therapy (HRT) uses hormones to replace natural hormones when the body's production is insufficient. For instance, hormone replacement therapy is usually given to thyroid patients and human growth hormone patients. Furthermore, HRT was often administered to menopausal women to alleviate indications such as night sweats, hot flushes, sleep disturbances, psychological and genito-urinary disorders (urinary frequency and vaginal dryness), and the prevention of osteoporosis. In addition, a survey of 2,000 American women aged 30 to 60 indicated that approximately 47% of the surveyed population experienced the symptoms of hormonal imbalance in 2019.

 

Menopause is the most frequently reported consequence of age-related hormonal changes. It often begins around the age of 50 in women around the world. By the age of 50, the levels of oestrogen and progesterone produced by women significantly decrease. The pituitary gland compensates for the decline in oestrogen and progesterone production by increasing the output of follicle-stimulating hormone.

Hormone Replacement Therapy Based on Market Share-2020

Drivers

  • The rise in prevalence of menopausal illness and increased awareness of post-menopausal difficulties among women are two significant factors driving the worldwide HRT market.

  • The hormone replacement therapy market trend is being driven by a large increase in the incidence rate of hormonal abnormalities in newborns, adults, and the elderly. Moreover, disease like The Prader-Willi syndrome (PWS) affects one out of every 15,000 babies.

  • Low-Dosevaginal estrogen therapy, topical estrogen therapy, hysterectomy with bilateral salpingo-oophorectomy, Systemic hormone therapy, and Bioidentical hormone replacement therapy are all the factors that drive the market globally.

 

Restraints

  • During the projected period, unfavorable effects of hormone replacement therapy are expected to restrain market expansion.

  • The high expense of hormone replacement therapy and the risk of acquiring cancer from HRTs are expected to stifle global market growth.

  • Risks involved in hormone replacement therapy include Heart disease, Stroke, Blood clots, and Breast cancer which are expected to restrain the market.

 

Key Opportunity

  • The need for bioidentical hormone replacement therapy and the use of telemedicine for hormone replacement therapy are projected to give a lucrative opportunity for the global hormone replacement therapy market to expand in the near future.

 

Market Analysis Of Different Segments Covered in the Report

By Route Of Administration

  • Oral

  • Parenteral

  • Others

 

Hormone Replacement Therapy Market Based on Therapy Type

 

Hormone Replacement Therapy Market By Therapy Type

  • Estrogen Hormone Replacement Therapy

  • Human Growth Hormone Replacement Therapy

  • Thyroid Hormone Replacement Therapy

  • Testosterone Hormone Replacement Therapy

  • Progestogen Hormone Replacement Therapy

 

By Indication

  • Menopause

  • Hypothyroidism

  • Male Hypogonadism

  • Growth Hormone Deficiency

  • Others

 

By Region

North America

  • United States

  • Canada

  • Mexico

 

Europe

  • Germany

  • France

  • Italy

  • Switzerland

  • UK

  • Rest of Europe

 

Asia-Pacific

  • Japan

  • China

  • India

  • Rest of Asia-Pacific

 

LAMEA

  • Brazil

  • Israel

  • South Africa

  • Saudi Arabia

  • Rest of LAMEA

 

Hormone Replacement Therapy Market Based on Region

Based on Route Of Administration, the oral market segment accounted for the largest proportion of the hormone replacement treatment market in 2020 and is predicted to increase at the quickest rate over the forecast period. This is because oral administration of testosterone medications is highly favored, and oral medication is the most prevalent form of oestrogen replacement therapy.

 

In terms of therapy type, estrogen hormone replacement therapy was the market leader in 2020. This is due to women's increased usage of estradiol products to help them maintain hormonal balance after menopause or hysterectomy. Dryness, burning, itching, and pain during intercourse are some of the vaginal symptoms of menopause that can be alleviated by oestrogen replacement hormone therapy. Estrogen can be taken as a Estrogenpill, gel, Estrogen patch, lotion, or spray. It has a good success rate in treating menopausal night sweats and hot flashes, around 45 percent of women aged 40 to 60 reported seeking medical advice on the benefits and drawbacks of utilizing hormone replacement therapy (HRT) after menopause.

 

Menopause is predicted to expand at the quickest rate in terms of indication from 2021 to 2028, as there is a great advancement in the number of postmenopausal women and the expansion of the menopausal window from 40 to 55 years. In accordance to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause every day.

 

According to World Health Organisation (WHO), around 15 million neonates are born prematurely, with approximately 85% of these children being underdeveloped. Hormone treatment is used in adults to treat disorders like short bowel syndrome and pituitary tumors.

 

The North American market dominated the global hormone replacement therapy market in 2019 due to the rise in manufacturer’s release of various generic hormone replacement therapy medicines, an increase in the target population, and advances in drug delivery technologies, as well as the creation of new formulations. Also, because of the rising public awareness, the hormone replacement treatment market in Asia Pacific is expected to grow quickly in the future years. Emerging countries such as Japan, India, and China will play a significant role in market expansion.

 

According to the NIH(National Institutes of Health), half of the postmenopausal women have used HRT at least once.

 

In 2014, more than 2.5 million Americans received testosterone treatment, according to the American Academy of Family Physicians.

 

In accordance to NIH, about half of all postmenopausal women in the United States had hormone replacement therapy (HRT) at some point in their life. In addition, roughly 1.3 million American women will enter the menopause phase each year by 2021, according to a study published in Statpearls.

 

According to studies conducted by organizations such as Rose Research, the North American Menopause Society (NAMS), and Therapeutic MD, approximately one million women in the United States are currently using hormone replacement therapy, which is expected to rise to 2.5 million in the near future.

 

According to a study published in the Journal of Menopausal Medicine in 2020, about 75 percent of women experience menopause symptoms between the ages of 45 and 55, resulting in decreased self-esteem.

 

According to the World Population Ageing 2019 study, women will account for 54 percent of the global population aged 65 and over by 2050, with a life expectancy at birth of 74.7 years in 2019.

 

According to the American Thyroid Association (ATA), more than 12% of the US population is expected to have a thyroid issue during their lifetime, and nearly 20 million Americans are impacted by thyroid illness each year. As a result of the significant prevalence of thyroid hormone imbalance among the people in the United States, the studied market in the region is predicted to grow.

 

Hormone Replacement Therapy Market Competitive Landscape Analysis

  • Abbott Laboratories

  • Bayer Ag.

  • Eli Lily And Company

  • Hoffmann-La Roche Ltd. (Genentech, Inc.)

  • Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)

  • Merck Kgaa

  • Mylan N.V. (Viatris Inc.)

  • Novartis International Ag

  • Novo Nordisk A/S

  • Pfizer Inc.

Hormone Replacement Therapy Market Report Coverage

Report Attribute

Details

Forecast Period

2021 - 2030

The market size value in 2021

USD 24.97 billion

The revenue forecast in 2030

USD 49.25 billion

Growth rate

CAGR of approximately  7.839%

The base year for estimation

2021

Historical data

2015 – 2019

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Route Of Administration, By Therapy Type, By Indication, By Region

By Route Of Administration

Oral, Parenteral, Others

By Therapy Type

Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, Progestogen Hormone Replacement Therapy

By Indication

Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Others

By Region

North America, Asia-Pacific, Europe, LAMEA

Country Scope

United States of America, Mexico, United Arab Emirates, United Kingdom, Germany, France, Canada, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, South Africa

Company Usability Profiles

Abbott Laboratories, Bayer Ag., Eli Lily And Company, Hoffmann-La Roche Ltd. (Genentech, Inc.), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S, Pfizer Inc.

 

Recent Developments

  • On August 16th, 2022, Akorn announced that it had successfully received FDA approval for launching its Generic-Cetrorelix Acetate in the form of Injection (0.25 mg quantity). Cetrorelix is one of the most effective chemicals used in hormone replacement therapy as it totally blocks the adverse impacts of a natural hormone, known as GnRH or gonadotropin-releasing hormone. During the treatment process of ovarian stimulation, premature ovulation can lead to the formation of eggs that are unsuitable for fertilization. The Cetrorelix Acetate present in the Injection blocks such kind of premature ovulation.

  • In December 2020, The US FDA approved Myovant Sciences' Orgovyx (relugolix). Orgovyx (relugolix) is an orally administered treatment that prevents the pituitary gland from producing luteinizing hormone and follicle-stimulating hormone, decreasing the amount of testosterone produced by the testicles. This aids in the treatment of advanced prostate cancer in adults.

  • In August 2020, Bayer AG announced the acquisition of KanDy Therapeutics Inc., which will help Bayer to expand its women's medicine pipeline by including menopausal treatment in its portfolio.

  • In August 2020, the FDA (US Food and Drug Administration) authorized Sogroya (somapacitan), a human growth hormone (HGH) therapy for adults with growth hormone insufficiency that is administered once a week via injection under the skin. As a result, the region's analyzed market is projected to be driven by the high trend of product approvals.

 

The Key Products that the Market Leaders Develop

Name of the product

Function

Key Players

THYROCAB

It is used in curing hyperthyroidism

Abbott Laboratories

 

ANGELIQ

It is used to reduce menopause symptoms

Bayer Inc.

Adakveo

It is used to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients.

Novartis International Ag

 

Frequently Asked Question About This Report

The global hormone replacement therapy market is expected to grow at a compound annual growth rate (CAGR) of 7.839% from 2021 to 2030 to reach USD $ 49.25 billion by 2030.

The global hormone replacement therapy market size was $24.97 billion in 2021 and is predicted to reach $49.25 billion by 2030, with a CAGR of 7.83%.

According to indication, the menopausal segment would grow at the quickest rate throughout the projected period, due to an increasing advancement in the number of postmenopausal women and the expansion of the menopausal window from 40 to 55 years.

The key players majorly operating in the Hormone Replacement Therapy Market areAbbott Laboratories, Bayer Ag.Eli Lily And Company, Pfizer Inc., Hisamitsu Pharmaceutical Co., Hoffmann-La Roche Ltd. (Genentech, Inc.), Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S,

In terms of therapy type, oestrogen hormone replacement therapy was the market leader in 2021.

The oral category accounted for the greatest proportion of the market in 2021

Sources

https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf

https://www.who.int/news-room/fact-sheets/detail/preterm-birth

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963523/

https://www.statpearls.com/ArticleLibrary/viewarticle/27522

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830366/

1.   Introduction

       1.1.  Study Objective

       1.2.  Market Definition        

       1.3.  Study Scope

              1.3.1. Markets Covered

              1.3.2. Geographic Scope

              1.3.3. Years Considered

              1.3.4. Stakeholders

2.   Research Methodology

       2.1.  Data Procurement

       2.2.  Paid Database

              2.2.1. Secondary Data

                     2.2.1.1. Key Secondary sources

              2.2.2. Primary Data

                     2.2.2.1 Primary sources

                     2.2.2.2. Key industry insights

                     2.2.2.3. Primary interviews with experts

                     2.2.2.4. Key primary respondent list

       2.3.  Market Size Estimation

       2.4.  Bottom-Up and Top-Down Approaches

              2.4.1.       Bottom-Up Approach

                     2.4.1.1.            Approach for arriving at market size by bottom-up analysis

              2.4.2.       Top-Down Approach

                     2.4.2.1.            Approach for Capturing Market Size by Top-Down Analysis

       2.5.  Market Breakdown and Data Triangulation

       2.6.  Research Methodology

       2.7.  Risk Assessment

3.  Executive Summary

       3.1   Post-Covid-19

              3.1.1        Actual Scenario

              3.1.2        Pessimistic Scenario

              3.1.3        Optimistic Scenario

              3.1.4        Market Summary

4. Industry Outlook

       4.1   Market Snapshot

       4.2   Global  Hormone Replacement Therapy Market

              4.2.1        Global  market, 2021 – 2030 (USD Million)

       4.3   Regional Business Analysis

              4.3.1        Global  market, by region, 2021 - 2030 (USD Million)

       4.4   By Therapy Type Business Analysis

              4.4.1        Global  market, By Therapy Type, 2021 - 2030 (USD Million)

       4.5   By Indication Business Analysis

              4.5.1        Global  market, By Indication, 2021 - 2030 (USD Million)

       4.6   Route Of Administration Business Analysis

              4.6.1        Global  market, By Route Of Administration, 2021 - 2030 (USD Million)

       4.7   Value Chain Analysis

       4.8   Market Variable Analysis

              4.8.1        Market Drivers Analysis

              4.8.2        Market Restraints Analysis

       4.9 Business Environment Analysis Tool

              4.9.1         market PEST analysis

              4.9.2         market Porter’s analysis

       4.10 Penetration & Growth Prospect Mapping

5. Market Dynamics

       5.1.  Introduction

       5.2.  Market Dynamics

              5.2.1.       Drivers

              5.2.2.       Restraints

              5.2.3.       Opportunities

              5.2.4.       Challenges

       5.3.  Impact of Covid-19 On  Market

       5.4.  Value Chain Analysis

       5.5.  Ecosystem

       5.6.  Patent Analysis

       5.7.  Trade Analysis

       5.8.  Tariff Analysis

       5.9.  Case Study Analysis

5.10.      Porter’s Five Forces Analysis

              5.10.1      Threat of New Entrants

              5.10.2      Threat of Substitutes

              5.10.3      Bargaining Power of Buyers

              5.10.4      Bargaining Power of Suppliers

              5.10.5      Degree of Competition

       5.11.               Route Of Administration Analysis

              5.11.1.     Trends in Route Of Administration (2014-2021)

              5.11.2.     Trends in Route Of Administration (2021-2030)

       5.12.               Pricing Analysis

              5.12.1.     Average Price Trend Analysis (By region, By Countries)

6. Competitive & Vendor Landscape

       6.1.  Company Market Share Analysis

       6.2.  Manufacturers  Manufacturing Sites, Area Served, Product Therapy Type

       6.3.   Market Competitive Situation and Trends

       6.4.  Manufacturers Mergers & Acquisitions, Expansion Plans

7. Global  Market: By Therapy Type Segment Analysis

       7.1.  Introduction

       7.2.  Sales Volume & Revenue Analysis (2021-2030)

       7.3.  Estrogen

              7.3.1. Estrogen  market, 2021 - 2030 (USD Million)

       7.4.  Human Growth

              7.4.1. Human Growth  market, 2021 - 2030 (USD Million)

       7.5.  Thyroid

              7.5.1. Thyroid  market, 2021 - 2030 (USD Million)

       7.6.  Testosterone

              7.6.1. Testosterone  market, 2021 - 2030 (USD Million)

       7.7.  Progestogen

              7.7.1. Progestogen  market, 2021 - 2030 (USD Million)

8. Global  Market: By Indication Segment Analysis

       8.1.  Introduction

       8.2.  Sales Volume & Revenue Analysis (2021-2030)

       8.3.  Menopause

              8.3.1.       Menopause market, 2021 - 2030 (USD Million)

       8.4.  Hypothyroidism

              8.4.1.       Hypothyroidism market, 2021 - 2030 (USD Million)

       8.5.  Male Hypogonadism

              8.5.1.       Male Hypogonadism market, 2021 - 2030 (USD Million)

       8.6. Growth Hormone Deficiency

              8.6.1.       Growth Hormone Deficiency market, 2021 - 2030 (USD Million)

       8.7.  Others

              8.7.1.       Others market, 2021 - 2030 (USD Million)

9. Global  Market: By Route Of Administration Segment Analysis

       9.1.  Introduction

       9.2.  Sales Volume & Revenue Analysis (2021-2030)

       9.3.  Oral

              9.3.1.       Oral market, 2021 - 2030 (USD Million)

       9.4.  Parenteral

              9.4.1.       Parenteral market, 2021 - 2030 (USD Million)

       9.5.  Others

              9.5.1.       Others market, 2021 - 2030 (USD Million)

10. Global  Market: Regional Outlook

       10.1 North America

              10.1.1.     North America   market, by By Therapy Type, 2021 - 2030 (USD Million)

              10.1.2.     North America   market, by By Indication, 2021 - 2030 (USD Million)

              10.1.3.     North America   market, by Route Of Administration, 2021 - 2030 (USD Million)

              10.1.4.     North America   market, by Country, 2021 - 2030 (USD Million)

       10.1.4.1. U.S.

                     10.1.4.1.1.      U.S.  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.1.4.1.2.      U.S.  market, by By Indication, 2021 - 2030 (USD Million)

                     10.1.4.1.3.      U.S.  market, by Route Of Administration, 2021 - 2030 (USD Million)

     10.1.4.2.  Canada

                     10.1.4.2.1.      Canada  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.1.4.2.2.      Canada  market, by By Indication, 2021 - 2030 (USD Million)

                     10.1.4.2.3.      Canada  market, by Route Of Administration, 2021 - 2030 (USD Million)

10.2. Europe

              10.2.1.     Europe  market, by By Therapy Type, 2021 - 2030 (USD Million)

              10.2.2.     Europe  market, by By Indication, 2021 - 2030 (USD Million)

              10.2.3.     Europe  market, by Route Of Administration, 2021 - 2030 (USD Million)

              10.2.4.     Europe  market, by country, 2021 - 2030 (USD Million)

    10.2.4.1    U.K.

                     10.2.4.1.1.      U.K.  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.2.4.1.2.      U.K.  market, by By Indication, 2021 - 2030 (USD Million)

                     10.2.4.1.3.      U.K.  market, by Route Of Administration, 2021 - 2030 (USD Million)

   10.2.4.2.            Germany

                     10.2.4.2.1.      Germany  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.2.4.2.2.      Germany  market, by By Indication, 2021 - 2030 (USD Million)

                     10.2.4.2.3.      Germany  market, by Route Of Administration, 2021 - 2030 (USD Million)

   10.2.4.3.            France

                     10.2.4.3.1.      France  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.2.4.3.2.      France  market, by By Indication, 2021 - 2030 (USD Million)

                     10.2.4.3.3.      France  market, by Route Of Administration, 2021 - 2030 (USD Million)

    10.2.4.4.           Rest of Europe

                     10.2.4.4.1.      Rest of Europe  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.2.4.4.2.      Rest of Europe  market, by By Indication, 2021 - 2030 (USD Million)

                     10.2.4.4.3.      Rest of Europe  market, by Route Of Administration, 2021 - 2030 (USD Million)

       10.3.               Asia Pacific

              10.3.1.     Asia Pacific  market, by By Therapy Type, 2021 - 2030 (USD Million)

              10.3.2.     Asia Pacific  market, by By Indication, 2021 - 2030 (USD Million)

              10.3.3.     Asia Pacific  market, by Route Of Administration, 2021 - 2030 (USD Million)

              10.3.4.     Asia Pacific  market, by country, 2021 - 2030 (USD Million)

   10.3.4.1.            China

                     10.3.4.1.1.      China  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.3.4.1.2.      China  market, by By Indication, 2021 - 2030 (USD Million)

                     10.3.4.1.3.      China  market, by Route Of Administration, 2021 - 2030 (USD Million)

   10.3.4.2.            India

                     10.3.4.2.1.      India  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.3.4.2.2.      India  market, by By Indication, 2021 - 2030 (USD Million)

                     10.3.4.2.3.      India   market, by Route Of Administration, 2021 - 2030 (USD Million)

   10.3.4.3.            Japan

                     10.3.4.3.1.      Japan  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.3.4.3.2.      Japan  market, by By Indication, 2021 - 2030 (USD Million)

                     10.3.4.3.3.      Japan  market, by Route Of Administration, 2021 - 2030 (USD Million)

   10.3.4.4.            South Korea

                     10.3.4.4.1.      South Korea  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.3.4.4.2.      South Korea  market, by By Indication, 2021 - 2030 (USD Million)

                     10.3.4.4.3.      South Korea  market, by Route Of Administration, 2021 - 2030 (USD Million)

10.3.4.5.               Rest of ASIA PACIFIC

                     10.3.4.5.1.      Rest of ASIA PACIFIC  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.3.4.5.2.      Rest of ASIA PACIFIC  market, by By Indication, 2021 - 2030 (USD Million)

                     10.3.4.5.3.      Rest of ASIA PACIFIC  market, by Route Of Administration, 2021 - 2030 (USD Million)

       10.4.               Latin America

              10.4.1.     Latin America  market, by By Therapy Type, 2021 - 2030 (USD Million)

              10.4.2.     Latin America  market, by By Indication, 2021 - 2030 (USD Million)

              10.4.3.     Latin America  market, by Route Of Administration, 2021 - 2030 (USD Million)

              10.4.4.     Latin America  market, by country, 2021 - 2030 (USD Million)

10.4.4.1.               Brazil

                     10.4.4.1.1.      Brazil  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.4.4.1.2.      Brazil  market, by By Indication, 2021 - 2030 (USD Million)

                     10.4.4.1.3.      Brazil  market, by Route Of Administration, 2021 - 2030 (USD Million)

10.4.4.2.               Mexico

                     10.4.4.2.1.      Mexico  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.4.4.2.2.      Mexico  market, by By Indication, 2021 - 2030 (USD Million)

                     10.4.4.2.3.      Mexico  market, by Route Of Administration, 2021 - 2030 (USD Million)

                     10.4.4.3.          Rest of the Latin America

                     10.4.4.3.1.      Rest of the Latin America  market, by By Therapy Type, 2021 - 2030 (USD Million)

                     10.4.4.3.2.      Rest of the Latin America  market, by By Indication, 2021 - 2030 (USD Million)

                     10.4.4.3.3.      Rest of the Latin America  market, by Route Of Administration, 2021 - 2030 (USD Million)

       10.5.               MEA

              10.5.1.     MEA  market, by By Therapy Type, 2021 - 2030 (USD Million)

              10.5.2.     MEA  market, by By Indication, 2021 - 2030 (USD Million)

              10.5.3.     MEA  market, by Route Of Administration, 2021 - 2030 (USD Million)

              10.5.4.     MEA  market, by Region, 2021 - 2030 (USD Million)

 

11. Competitive Landscape

       11.1 Abbott Laboratories

              11.1.1.     Company overview

              11.1.2.     Financial performance

              11.1.3.     Product Portfolio Analysis

              11.1.4.     Business Strategy & Recent Development

       11.2. Bayer Ag

              11.2.1.     Company overview

              11.2.2.     Financial performance

              11.2.3.     Product Portfolio Analysis

              11.2.4.     Business Strategy & Recent Development

       11.3. Eli Lily And Company

              11.3.1.     Company overview

              11.3.2.     Financial performance

              11.3.3.     Product Portfolio Analysis

              11.3.4.     Business Strategy & Recent Development

       11.4. Hoffmann-La Roche Ltd. (Genentech, Inc.)

              11.4.1.     Company overview

              11.4.2.     Financial performance

              11.4.3.     Product Portfolio Analysis

              11.4.4.     Business Strategy & Recent Development

       11.5. Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)

              11.5.1.     Company overview

              11.5.2.     Financial performance

              11.5.3.     Product Portfolio Analysis

              11.5.4.     Business Strategy & Recent Development

       11.6. Merck Kgaa

              11.6.1.     Company overview

              11.6.2.     Financial performance

              11.6.3.     Product Portfolio Analysis

              11.6.4.     Business Strategy & Recent Development

       11.7. Mylan N.V. (Viatris Inc.)

              11.7.1.     Company overview

              11.7.2.     Financial performance

              11.7.3.     Product Portfolio Analysis

              11.7.4.     Business Strategy & Recent Development

       11.8. Novartis International Ag

              11.8.1.     Company overview

              11.8.2.     Financial performance

              11.8.3.     Product Portfolio Analysis

              11.8.4.     Business Strategy & Recent Development

       11.9. Novo Nordisk A/S

              11.9.1.     Company overview

              11.9.2.     Financial performance

              11.9.3.     Product Portfolio Analysis

              11.9.4.     Business Strategy & Recent Development

       11.10. Pfizer Inc.

              11.10.1.  Company overview

              11.10.2.  Financial performance

              11.10.3.  Product Portfolio Analysis

              11.10.4.  Business Strategy & Recent Development

 

List of Tables (53 Tables)

TABLE 1.   MARKET, By Therapy Type, 2021-2030 (USD Million)

TABLE 2.   MARKET FOR Estrogen , BY REGION, 2021-2030 (USD Million)

TABLE 3.   MARKET FOR Human Growth , BY REGION, 2021-2030 (USD Million)

TABLE 4.   MARKET FOR Thyroid , BY REGION, 2021-2030 (USD Million)

TABLE 5.   MARKET FOR Testosterone , BY REGION, 2021-2030 (USD Million)

TABLE 6.   MARKET FOR Progestogen , BY REGION, 2021-2030 (USD Million)

TABLE 7.  MARKET, By Indication, 2021-2030 (USD Million)

TABLE 8.  MARKET FOR Menopause, BY REGION, 2021-2030 (USD Million)

TABLE 9.  MARKET FOR Hypothyroidism, BY REGION, 2021-2030 (USD Million)

TABLE 10.  MARKET FOR Male Hypogonadism, BY REGION, 2021-2030 (USD Million)

TABLE 11.  MARKET FOR Growth Hormone Deficiency, BY REGION, 2021-2030 (USD Million)

TABLE 12.  MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 13.  MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million)

TABLE 14.  MARKET FOR Oral, BY REGION, 2021-2030 (USD Million)

TABLE 15.  MARKET FOR Parenteral, BY REGION, 2021-2030 (USD Million)

TABLE 16.  MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 17.  MARKET, BY REGION, 2021-2030 (USD Million)

TABLE 18. NORTH AMERICA  MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 19. NORTH AMERICA  MARKET, By Therapy Type, 2021-2030 (USD Million)

TABLE 20. NORTH AMERICA  MARKET, By Indication, 2021-2030 (USD Million)

TABLE 21. NORTH AMERICA  MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million)

TABLE 22. EUROPE  MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 23. EUROPE  MARKET, By Therapy Type, 2021-2030 (USD Million)

TABLE 24. EUROPE  MARKET, By Indication, 2021-2030 (USD Million)

TABLE 25. EUROPE  MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million)

TABLE 26. ASIA-PACIFIC  MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 27. ASIA-PACIFIC  MARKET, By Therapy Type, 2021-2030 (USD Million)

TABLE 28. ASIA-PACIFIC  MARKET, By Indication, 2021-2030 (USD Million)

TABLE 29. ASIA-PACIFIC  MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million)

TABLE 30. LAMEA  MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 31. LAMEA  MARKET, By Therapy Type, 2021-2030 (USD Million)

TABLE 32. LAMEA  MARKET, By Indication, 2021-2030 (USD Million)

TABLE 33. LAMEA  MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million)

TABLE 34. Abbott Laboratories: COMPANY SNAPSHOT

TABLE 35. Abbott Laboratories: OPERATING SEGMENTS

TABLE 36. Bayer Ag: COMPANY SNAPSHOT

TABLE 37. Bayer Ag: OPERATING SEGMENTS

TABLE 38. Eli Lily And Company: COMPANY SNAPSHOT

TABLE 39. Eli Lily And Company: OPERATING SEGMENTS

TABLE 40. Hoffmann-La Roche Ltd. (Genentech, Inc.): COMPANY SNAPSHOT

TABLE 41. Hoffmann-La Roche Ltd. (Genentech, Inc.): OPERATING SEGMENTS

TABLE 42. Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.): COMPANY SNAPSHOT

TABLE 43. Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.): OPERATING SEGMENTS

TABLE 44. Merck Kgaa: COMPANY SNAPSHOT

TABLE 45. Merck Kgaa: OPERATING SEGMENTS

TABLE 46. Mylan N.V. (Viatris Inc.): COMPANY SNAPSHOT

TABLE 47. Mylan N.V. (Viatris Inc.): OPERATING SEGMENTS

TABLE 48. Novartis International Ag: COMPANY SNAPSHOT

TABLE 49. Novartis International Ag: OPERATING SEGMENTS

TABLE 50. Novo Nordisk A/S: COMPANY SNAPSHOT

TABLE 51. Novo Nordisk A/S: OPERATING SEGMENTS

TABLE 52. Pfizer Inc: COMPANY SNAPSHOT

TABLE 53. Pfizer Inc: OPERATING SEGMENTS

 

List of Figures (21 Figures)

Figure 1  Market: Research Methodology Steps

Figure 2 Research Design

Figure 3 Breakdown of Primaries:  Market

Figure 4 Research Methodology: Hypothesis Building

Figure 5  Market: Product-Based Estimation

Figure 6 Top 10 Companies with Highest No. Of Patent in Last 9 Years

Figure 7 No. Of Patents Granted Per Year, 2019–2021

Figure 8 Import Data for Hormone Replacement Therapy, By Country, 2016–2021 (USD Thousand)

Figure 9 Export Data for Hormone Replacement Therapy, By Country, 2016–2021 (USD Thousand)

Figure 10 Data Triangulation Methodology

Figure 11  Market, By Indication, 2019 vs. 2025 (USD Million)

Figure 12  Market Share, By Route Of Administration, 2019 vs. 2025 (USD Million)

Figure 13  Market Share, By Therapy Type, 2019 vs. 2025 (USD Million)

Figure 14 Geographical Snapshot of the  Market

Figure 15 Estrogen  to Witness Higher CAGR in  Market for Therapy Type Segment during Forecast Period.

Figure 16 Oral to Witness Higher CAGR in  Market for Route Of Administration Segment during Forecast Period.

Figure 17 Menopause to Witness Higher CAGR in  Market for Indication Segment during Forecast Period.

Figure 18 North America Accounted for the Largest Share of the  Market, By Regional Basis, in 2019

Figure 19  Market: Drivers, Restraints, Opportunities, and Challenges

Figure 20 North America:  Market Snapshot

Figure 21 Asia Pacific:  Market Snapshot

Figure 22 Vendor Dive: Evaluation Overview

 

Choose License Type


$4485
$6449
$8339
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization
Related Reports
Buy Now
Request Sample

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: +1-315-636-4233
  • UK: +44-162-237-0614
  • IN: +91-826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved.